Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Colorcon
Harvard Business School
Medtronic
Boehringer Ingelheim

Last Updated: August 8, 2022

Investigational Drug Information for AZD-9164


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for AZD-9164?

AZD-9164 is an investigational drug.

There have been 32 clinical trials for AZD-9164. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2006.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Ovarian Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

Recent Clinical Trials for AZD-9164
TitleSponsorPhase
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsAstraZenecaPhase 2
Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer SubjectsSamsung Medical CenterPhase 2
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2

See all AZD-9164 clinical trials

Clinical Trial Summary for AZD-9164

Top disease conditions for AZD-9164
Top clinical trial sponsors for AZD-9164

See all AZD-9164 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Colorcon
Harvard Business School
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.